Current Studies Open to Enrollment
Current Studies
We are currently enrolling patients into the studies listed below. Patients need to meet the criteria for study enrollment before entry into these clinical trials. Please contact us if you would like to consider participating in one of these studies.
Seizures
GlaxoSmithKline – LEP105972
Lamictal XR
A Multicenter, Double-Blind, Randomized, Parallel-Group Evaluation of LAMICTAL XR Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
King Pharmaceuticals – K826-05-3001
Vanquix
A Phase 3, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multicenter Study, with Optional Open-Label Continuation, of the efficacy and Safety of Vanquix ™ Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory, Patients with Epilepsy who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures
Pfizer Pharmaceuticals – A0081074
Lyrica (peds)
A Placebo-Controlled, Escalating Dose, Multiple Dose Study to Evaluate the Safety, Tolerability and Phamacokinetics of Pregabalin in Pediatric Patients with Partial Onset Seizures
Schwarz - SP902
Lacosamide
A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Mono-therapy in Subjects with Partial-onset Seizures
Migraine
NINDS/Emmes Corporation - CMTT
Chronic Migraine Treatment Trial (CMTT)
The Chronic Migraine Treatment Trial (CMTT) is a streamlined, double-blind, placebo-controlled randomized clinical trial expected to randomize 250 participants with chronic migraine across at least 50 sites to either treatment with topiramate (up to 100 mg/day) and propranolol (up to 240 mg/day LA formulation) or treatment with topiramate (up to 100 mg/day) and placebo. Randomized participants will be followed for six months with the primary objective to assess the efficacy and safety of propranolol in combination with topiramate for reducing the number of days with severe headache (at least moderate in severity, lasting at least 4 hours during a 28-day interval) following six months of treatment.
Stroke
CoAxia – MA 0027
SENTIS
Safety and Efficacy of Neuro-Flo Technology in Ischemic Stroke
Cordis - HUD
ENTERPRISE
Vascular Reconstruction Device and Delivery System (A Humanitarian Use Device)
Concentric Medical – INT-REG-001
MERCI REGISTRY
Prospective, Open-Label, Competitive Enrollment, Multi-center, Multi-National Registry
Cordis – P06-3603
SAPPHIRE
Stenting And Angioplasty With Protection In Patients At High-Risk For Endarterectomy
Penumbra – CLP1953.A
Penumbra Imaging Collaborative Study (PICS)
A Multicenter Trial to Assess Outcone of Patients Revascularized by the Penumbra™ System
NINDS
Interventional Management of Stroke Study III (IMS III)
A Phase III, Randomized, Multi-Center, Open Label, 900 Subject Clinical Trial That Will Examine Whether a Combined Intravenous (IV) and Intra-arterial (IA) Approach to Recanalization is Superior to Standard IV rt-PA (Activase) Alone When Initiated Within Three Hours of Acute Ischemic Stroke Onset.
Multiple Sclerosis
Biogen-Idec – 109MS302
BG000012
A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG000012 in Subjects with Relapsing-Remitting Multiple Sclerosis (CONFIRM)
Investigator Initiated Study - (Stephen S. Kirzinger - with support from Bayer Healthcare)
Neuropsychological Assessments in the Multiple Sclerosis Clinic
